DocWire News recently spoke with Dr. Jim Woody, CEO of 180 Life Sciences, a company that develops new treatments for inflammation. Dr. Woody and his team have now fully enrolled phase 2/3 study for the treatment of Dupuytren’s contracture. See what he had to say.

Created by an industry veteran with more than 20 years’ experience, Protodigm aims to offer innovation and expertise to pharmaceutical industry clients.

Amgen and Kyowa Kirin capped off a decadeslong partnership in 2017, when the Big Biotech handed over $780 million to subsume their joint venture. Now, the duo is back at it in a new deal around a phase-3-ready asset worth $400 million upfront. In exchange for that $400 million and the promise of milestones worth […]